B cells require Type 1 interferon to produce alloantibodies to transfused KEL-expressing red blood cells in mice

Transfusion

Volumn 57, Issue 11, 2017, Pages 2595-2608

  Gibb, David R ^a   Liu, Jingchun ^a   Santhanakrishnan, Manjula ^a   Natarajan, Prabitha ^a   Madrid, David J ^a   Patel, Seema ^c   Eisenbarth, Stephanie C ^a,b   Tormey, Christopher A ^a,d   Stowell, Sean R ^c   Iwasaki, Akiko ^b,e   Hendrickson, Jeanne E ^a  

^a Department of Laboratory Medicine ^*  (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ALPHA BETA INTERFERON RECEPTOR; ALPHA INTERFERON; ERYTHROCYTE ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G; KEL ANTIGEN; UNCLASSIFIED DRUG; IFNAR1 PROTEIN, MOUSE; INTERFERON;

ALLOIMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BONE MARROW; CELL DIFFERENTIATION; CHIMERA; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; GERMINAL CENTER; MOUSE; MURINE MODEL; NONHUMAN; PLASMA CELL; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; BLOOD GROUP KELL SYSTEM; CYTOLOGY; GENETICS; IMMUNOLOGY; INFLAMMATION; LEUKAPHERESIS; PROCEDURES;

ANIMALS; B-LYMPHOCYTES; CELL DIFFERENTIATION; ERYTHROCYTE TRANSFUSION; GERMINAL CENTER; IMMUNOGLOBULIN G; INFLAMMATION; INTERFERON TYPE I; ISOANTIBODIES; KELL BLOOD-GROUP SYSTEM; LEUKOCYTE REDUCTION PROCEDURES; MICE; PLASMA CELLS; RECEPTOR, INTERFERON ALPHA-BETA;

EID: 85032899479     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14288     Document Type: Article

References (54)

1. Pfuntner A, Wier LM, Stocks C. Most frequent procedures performed in U.S. Hospitals, 2010: Statistical Brief #149. Rockville (MD): Healthcare Cost and Utilization Project (HCUP); 2006.
2. Körmöczi GF, Mayr WR. Responder individuality in red blood cell alloimmunization. Transfus Med Hemother 2014;41:446-51.
3. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012;120:528-37.
4. Fatalities reported to the FDA following blood collection and transfusion: annual summary for fiscal year 2014 [Internet]. 2014 [cited 2016 Nov 11]. Available from: http://www.fda.gov/downloads/biologicsbloodvaccines/safetyavailability/reportaproblem/transfusiondonationfatalities/ucm459461.pdf.
5. Nickel RS, Hendrickson JE, Fasano RM, et al. Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series. Transfusion 2016;56:107-14.
6. Telen MJ, Afenyi-Annan A, Garrett ME, et al. Alloimmunization in sickle cell disease: changing antibody specificities and association with chronic pain and decreased survival. Transfusion 2015;55:1378-87.
7. Fasano RM, Booth GS, Miles M, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol 2015;168:291-300.
8. Ramsey G, Smietana SJ. Multiple or uncommon red cell alloantibodies in women: association with autoimmune disease. Transfusion 1995;35:582-6.
9. Ryder AB, Hendrickson JE, Tormey CA. Chronic inflammatory autoimmune disorders are a risk factor for red blood cell alloimmunization. Br J Haematol 2015;174:483-5.
10. Papay P, Hackner K, Vogelsang H, et al. High risk of transfusion-induced alloimmunization of patients with inflammatory bowel disease. Am J Med 2012;125:717 e1-8.
11. Yazer MH, Triulzi DJ, Shaz B, et al. Does a febrile reaction to platelets predispose recipients to red blood cell alloimmunization? Transfusion 2009;49:1070-5.
12. Evers D, van der Bom JG, Tijmensen J, et al. Red cell alloimmunisation in patients with different types of infections. Br J Haematol 2016;175:956-66.
13. Bao W, Yu J, Heck S, et al. Regulatory T-cell status in red cell alloimmunized responder and nonresponder mice. Blood 2009;113:5624-7.
14. Ryder AB, Zimring JC, Hendrickson JE. Factors influencing RBC alloimmunization: lessons learned from murine models. Transfus Med Hemother 2014;41:406-19.
15. Yu J, Heck S, Yazdanbakhsh K. Prevention of red cell alloimmunization by CD25 regulatory T cells in mouse models. Am J Hematol 2007;82:691-6.
16. Hendrickson J, Roback JD, Hillyer CD, et al. Discrete toll like receptor agonists have differential effects on alloimmunization to red blood cells. Transfusion 2008;48:1869-77.
17. Arneja A, Salazar JE, Jiang W, et al. Interleukin-6 receptor-alpha signaling drives anti-RBC alloantibody production and T-follicular helper cell differentiation in a murine model of red blood cell alloimmunization. Haematologica 2016;101:e440-e4.
18. McNab F, Mayer-Barber K, Sher A, et al. Type I interferons in infectious disease. Nat Rev Immunol 2015;15:87-103.
19. Le Bon A, Schiavoni G, D'Agostino G, et al. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001;14:461-70.
20. Proietti E, Bracci L, Puzelli S, et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 2002;169:375-83.
21. Le Bon A, Thompson C, Kamphuis E, et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 2006;176:2074-8.
22. Müller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interferons in antiviral defense. Science 1994;264:1918-21.
23. Davidson S, Crotta S, McCabe TM, et al. Pathogenic potential of interferon αβ in acute influenza infection. Nat Commun 2014;5:3864.
24. Teijaro JR, Ng C, Lee AM, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013;340:207-11.
25. Wilson EB, Yamada DH, Elsaesser H, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013;340:202-7.
26. Assassi S, Mayes MD, Arnett FC, et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum 2010;62:589-98.
27. Båve U, Nordmark G, Lövgren T, et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52:1185-95.
28. Higgs BW, Liu Z, White B, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011;70:2029-36.
29. Olsen N, Sokka T, Seehorn CL, et al. A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis 2004;63:1387-92.
30. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610-5.
31. Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003;36:481-90.
32. Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2951-62.
33. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982;25:401-6.
34. Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013;65:1011-21.
35. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60:1785-96.
36. Kontos S, Grimm AJ, Hubbell JA. Engineering antigen-specific immunological tolerance. Curr Opin Immunol 2015;35:80-8.
37. Grimm AJ, Kontos S, Diaceri G, et al. Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigens. Sci Rep 2015;5:15907.
38. Smith NH, Henry KL, Cadwell CM, et al. Generation of transgenic mice with antithetical KEL1 and KEL2 human blood group antigens on red blood cells. Transfusion 2012;52:2620-30.
39. Calabro S, Gallman A, Gowthaman U, et al. Bridging channel dendritic cells induce immunity to transfused red blood cells. J Exp Med 2016;213:887-96.
40. Gibb DR, Calabro S, Liu D, et al. The Nlrp3 Inflammasome does not regulate alloimmunization to transfused red blood cells in mice. EBioMedicine 2016;9:77-86.
41. Stowell SR, Girard-Pierce KR, Smith NH, et al. Transfusion of murine red blood cells expressing the human KEL glycoprotein induces clinically significant alloantibodies. Transfusion 2014;54:179-89.
42. Gibb DR, El Shikh M, Kang DJ, et al. ADAM10 is essential for Notch2-dependent marginal zone B cell development and CD23 cleavage in vivo. J Exp Med 2010;207:623-35.
43. Ito T, Amakawa R, Inaba M, et al. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol 2001;166:2961-9.
44. Montoya M, Schiavoni G, Mattei F, et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 2002;99:3263-71.
45. Meredith MM, Liu K, Darrasse-Jeze G, et al. Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. J Exp Med 2012;209:1153-65.
46. Havenar-Daughton C, Kolumam GA, Murali-Krishna K. Cutting edge: the direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J Immunol 2006;176:3315-9.
47. Coro ES, Chang WL, Baumgarth N. Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection. J Immunol 2006;176:4343-51.
48. Fink K, Lang KS, Manjarrez-Orduno N, et al. Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses. Eur J Immunol 2006;36:2094-105.
49. Poeck H, Wagner M, Battiany J, et al. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 2004;103:3058-64.
50. Diamond MS, Kinder M, Matsushita H, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011;208:1989-2003.
51. Douagi I, Gujer C, Sundling C, et al. Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacytoid dendritic cells. J Immunol 2009;182:1991-2001.
52. Jego G, Palucka AK, Blanck JP, et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003;19:225-34.
53. Zhu J, Huang X, Yang Y. Type I IFN signaling on both B and CD4 T cells is required for protective antibody response to adenovirus. J Immunol 2007;178:3505-10.
54. Bach P, Kamphuis E, Odermatt B, et al. Vesicular stomatitis virus glycoprotein displaying retrovirus-like particles induce a type I IFN receptor-dependent switch to neutralizing IgG antibodies. J Immunol 2007;178:5839-47.